Chan, Stephen LStephen LChanSchuler, MartinMartinSchulerKang, Yoon-KooYoon-KooKangYen, Chia-JuiChia-JuiYenEdeline, JulienJulienEdelineChoo, Su PinSu PinChooCHIA-CHI LINOkusaka, TakujiTakujiOkusakaWeiss, Karl-HeinzKarl-HeinzWeissMacarulla, TeresaTeresaMacarullaCattan, StéphaneStéphaneCattanBlanc, Jean-FredericJean-FredericBlancLee, Kyung-HunKyung-HunLeeMaur, MichelaMichelaMaurPant, ShubhamShubhamPantKudo, MasatoshiMasatoshiKudoAssenat, EricEricAssenatZhu, Andrew XAndrew XZhuYau, ThomasThomasYauLim, Ho YeongHo YeongLimBruix, JordiJordiBruixGeier, AndreasAndreasGeierGuillén-Ponce, CarmenCarmenGuillén-PonceFasolo, AngelicaAngelicaFasoloFinn, Richard SRichard SFinnFan, JiaJiaFanVogel, ArndtArndtVogelQin, ShukuiShukuiQinRiester, MarkusMarkusRiesterKatsanou, VasilikiVasilikiKatsanouChaudhari, MonicaMonicaChaudhariKakizume, TomoyukiTomoyukiKakizumeGu, YiYiGuPorta, Diana GrausDiana GrausPortaMyers, AndreaAndreaMyersDelord, Jean-PierreJean-PierreDelord2024-01-122024-01-122022-06-021756-9966https://scholars.lib.ntu.edu.tw/handle/123456789/638435Deregulation of FGF19-FGFR4 signaling is found in several cancers, including hepatocellular carcinoma (HCC), nominating it for therapeutic targeting. FGF401 is a potent, selective FGFR4 inhibitor with antitumor activity in preclinical models. This study was designed to determine the recommended phase 2 dose (RP2D), characterize PK/PD, and evaluate the safety and efficacy of FGF401 alone and combined with the anti-PD-1 antibody, spartalizumab.enFGF19; FGFR4; Hepatocellular carcinoma; Immune checkpoint inhibitors; KLB; PD-1; PD-L1; Phase 1[SDGs]SDG3journal article10.1186/s13046-022-02383-5356553202-s2.0-85131125571https://api.elsevier.com/content/abstract/scopus_id/85131125571